No connection

Search Results

MIRM vs TGTX

MIRM
Mirum Pharmaceuticals, Inc.
BEARISH
Price
$96.49
Market Cap
$5.82B
Sector
Healthcare
AI Confidence
85%
TGTX
TG Therapeutics, Inc.
NEUTRAL
Price
$36.96
Market Cap
$5.9B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
MIRM
--
TGTX
13.34
Forward P/E
MIRM
-888.74
TGTX
15.01
P/B Ratio
MIRM
15.91
TGTX
8.17
P/S Ratio
MIRM
11.17
TGTX
9.58
EV/EBITDA
MIRM
2731.73
TGTX
45.15

Profitability

Gross Margin
MIRM
80.77%
TGTX
83.66%
Operating Margin
MIRM
-3.07%
TGTX
26.22%
Profit Margin
MIRM
-4.48%
TGTX
72.56%
ROE
MIRM
-8.65%
TGTX
102.75%
ROA
MIRM
-1.83%
TGTX
9.39%

Growth

Revenue Growth
MIRM
49.8%
TGTX
78.0%
Earnings Growth
MIRM
--
TGTX
-6.1%

Financial Health

Debt/Equity
MIRM
1.02
TGTX
0.39
Current Ratio
MIRM
2.67
TGTX
4.1
Quick Ratio
MIRM
2.46
TGTX
2.91

Dividends

Dividend Yield
MIRM
--
TGTX
--
Payout Ratio
MIRM
0.0%
TGTX
0.0%

AI Verdict

MIRM BEARISH

MIRM exhibits severe fundamental weakness with a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company shows impressive revenue growth of 49.8% and strong gross margins, this is offset by a lack of profitability and an extremely stretched valuation (P/B of 15.91). There is a stark divergence between the 'strong_buy' analyst consensus and the bearish reality of aggressive insider selling by the CEO, CFO, and President. The combination of a bearish technical trend (10/100) and deteriorating deterministic scores suggests the current price is speculative and unsupported by fundamentals.

Strengths
Strong YoY revenue growth of 49.80%
Excellent gross margins at 80.77%
Healthy short-term liquidity with a current ratio of 2.67
Risks
Critically low Piotroski F-Score (2/9) indicating weak financial health
Aggressive insider selling across C-suite executives (CEO, CFO, President)
Extreme valuation multiples (Price/Book: 15.91, Price/Sales: 11.17)
TGTX NEUTRAL

TGTX exhibits a stable financial foundation with a Piotroski F-Score of 6/9 and exceptional profitability margins, yet it faces a significant valuation gap. The stock is trading at $36.96, which is nearly double its Graham Number ($16.79) and Intrinsic Value ($19.39). While revenue growth is explosive at 78%, the company has missed earnings estimates in four consecutive quarters with an average surprise of -41.54%, and YoY earnings growth has turned negative (-6.10%). The disconnect between strong top-line growth and failing bottom-line expectations creates a high-risk profile despite the 'Buy' analyst consensus.

Strengths
Exceptional profit margins (72.56%) and gross margins (83.66%)
Strong liquidity with a Current Ratio of 4.10 and Quick Ratio of 2.91
Explosive YoY revenue growth of 78.00%
Risks
Severe valuation premium over Graham and Intrinsic value baselines
Consistent earnings misses (0/4 beats in the last 4 quarters)
Negative YoY earnings growth (-6.10%) despite revenue surge

Compare Another Pair

MIRM vs TGTX: Head-to-Head Comparison

This page compares Mirum Pharmaceuticals, Inc. (MIRM) and TG Therapeutics, Inc. (TGTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile